๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Nektar Therapeutics (NKTR)
NASDAQ: NKTR ยท Real-Time Price ยท USD
30.20
-2.34 (-7.19%)
Nov 20, 2026, 4:00 PM EST - Market closed
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

REZPEG's phase II profile showed deep, durable responses in AD and AA, supporting pivotal programs. AD phase III began in summer 2026; AA phase III is slated for December 2026, with first AD readouts expected mid-2028.

Roger Song
Senior Analyst of US SMID Cap Biotech, Jefferies

Welcome, everyone, to 2026 Jefferies Global Healthcare Conference in London. My name is Roger Song, Senior Analyst, cover SMID cap biotech in the U.S. It is my pleasure to have a fireside chat with our company, Nektar Therapeutics. J.Z., the Head of R&D, with me today. J.Z., why not you start with some very high-level overview of Nektar, where you are now, and then where you are heading to, and then we can talk some of the details about your pipeline.

Jonathan Zalevsky
Head of R&D, Nektar Therapeutics

Sure, and thank you very much, Roger, and thank you to Jefferies for the invite to the conference this year. We are very pleased to be here. At Nektar, we have been really focusing on our experience in immune regulation and understanding how to address indications in the I&I spectrum. We have been focused on the Treg targeting space, or regulatory T cells. Very topical, as it was the subject of last year's Nobel Prize, the discovery of immune tolerance, as well as the discovery of Tregs to Doctors Sakaguchi, Ramsdell, and Brunkow. We have been working on a molecule called rezpegaldesleukin, which is, to our knowledge, the most advanced regulatory T cell targeting agent. We have recently posted very strong phase II data in two different indications with REZPEG.

The first of these was in patients with moderate to severe atopic dermatitis, where we showed REZPEG in a dose-dependent fashion could induce a very rapid resolution of significant disease symptoms such as itch and skin clearance. Then with repeated dosing out to 52 weeks, we saw patients continue to not just achieve and keep their response, but continue to improve on the quality of that response. One of the things we observed in our 52-week maintenance was that patients treated up to a year, one in three people actually achieved an EASI- 100 score, or complete skin clearance. We were able to achieve that on a once a quarter or every 12-week dosing regimen.

Things that really started to differentiate REZPEG as a novel mechanism of action, as a kind of an agent where the effect builds up with time, great durability of the response, and some very deep efficacy benchmarks that were reached at one year. We followed that up with a study in patients with severe to very severe alopecia areata, where we saw patients treated through 52 weeks were able to achieve efficacy right in line with the JAK inhibitor. We used the Olumiant benchmark to guide to our TPP. We were able to achieve that Olumiant bar.

We saw this other very important feature of REZPEG's mechanism in that after one year of treatment, we followed patients for six months off drug, and the purpose was to assess durability of the hair the patients regrew, because we knew in this field, the patients treated with the JAK inhibitor could grow hair, but when they stopped the JAK inhibitor, they lost their hair. And we saw the majority of people not just keep their hair, but many people continued to grow additional hair in the six months off drug. And we saw the SALT 10 score, which is 90% or greater hair regrowth of their scalp, that rate actually tripled over the six-month off-drug period.

When we take a step back and we think about the novelty of a regulatory T cell mechanism, the ability for REZPEG to consistently control regulatory T cell pharmacology and to achieve all of the kind of clinical pharmacology needs that you need when you administer a biologic to patients chronically, and the kind of benchmarks we've hit across these indications, it makes us very excited about our positioning. And to that end, we've just kicked off the phase III registrational program for REZPEG in atopic dermatitis. Three pivotal studies, all of them are underway. That whole program kicked off in the summer of 2026. And in the coming weeks, in December of this year, we'll kick off the registrational program of REZPEG in alopecia areata, all building on this phase II results that I just mentioned, and being really a very exciting time for Nektar.

We'll expect the first of the top-line readouts from the phase III in the middle of 2028.

Roger Song
Senior Analyst of US SMID Cap Biotech, Jefferies

Excellent. Thanks, J.Z. Log me on at Nektar, and then I have to resonate with the novelty of the Treg, because we follow pretty closely the atopic dermatitis and the entire I&I space, and not many times we will see those real new mechanism with a very interesting property and the profile. Okay, let's dive in on the atopic dermatitis. The next data update actually is the 1Q next year. You have 52 weeks off treatment after the one-year maintenance. Tell us a little bit more about the design, because you are benchmarked to the Dupi 50%, kind of a nine months off treatment on the maintenance withdrawal. What's the difference and the similarity compared to that benchmark? And then have some specifics.

Jonathan Zalevsky
Head of R&D, Nektar Therapeutics

Yeah, sure. Firstly, just to set the table, we have observed with REZPEG from even our earliest phase I study that there was a unique off-drug durability to the mechanism. Just briefly, to remind everyone, we did a small phase I study where we treated about 40 patients in the whole trial, but we treated for 12 weeks with REZPEG, and then we followed people for nine months off drug. It was a true observation. We just followed patients. They would come back to the clinic with no additional treatment of any kind. We saw very deep durability of response, both for EASI-75 and the IGA, and that maintenance was maintained for nine months. That was an interesting observation in a small phase I study, and we wanted to be more prospective about assessing that as a differentiating feature of the mechanism.

In the phase II, we built in a one-year off-drug observation after patients were treated for one year in the atopic dermatitis setting. I commented on the efficacy benchmarks we hit at one year of treatment, and now in this off-drug period, there will be about 125 people that completed the 52-week treatment in the phase II. Of those, 15 are on placebo and 110 are on drug. The placebo people and others were there to maintain the blind. Even though it was just an observation, it was still blinded to the investigators and to the patients. The way the study was designed is we basically have quarterly disease assessments. There is, in total, five, a one-month follow-up followed by quarterly assessments afterwards out to one year.

This really gives us a chance to look at what happened after one year of treatment, now looking at one year of off-drug durability, and we will look to see if patients that reached a response, how well they could maintain it, and also if there was any improvement or deepening of response off drug as well. There really are not a lot of benchmarks for this, because this is such a novel sort of element and novel way to even approach observing a drug in this patient population. There are a couple of benchmarks that we are going to key into. In a number of phase III studies, when a maintenance regimen is tested, the health authorities often ask for a withdrawal kind of component.

For example, with Dupixent in the SOLO-CONTINUE, they tested after induction, re-randomizing patients to either stay on a treatment of Dupixent or move on to a sham injection of placebo. In that setting, even people that are on placebo, they do not know they are on placebo, as it is a randomized withdrawal. They are getting an injection, they just do not know if it is drug or placebo. Under those conditions, over a nine-month period, Dupixent demonstrated about a 50% maintenance of EASI-75 across that nine-month period with the placebo withdrawal and the sham injections. Our study, again, is different because there is no sham injection. It is just a direct observation. But the closest benchmark is that Dupixent analog, and that is why we were discussing a 50%. Dupixent hit that at nine months. Our study is 12 months.

If we reach that point at 12 months or even exceed it, we think that will be very notable. Based on some of our early data that I mentioned, I think it is quite reasonable that we could do that.

Roger Song
Senior Analyst of US SMID Cap Biotech, Jefferies

Excellent. Clarification on the 125 patient. Are they all EASI-75 responder, and then how about the Dupi withdrawal score?

Jonathan Zalevsky
Head of R&D, Nektar Therapeutics

Yeah, so that is the patients that completed. Not all of those patients will be EASI-75 responders. So, when we look at maintenance, we will be looking at the population or proportion that were responders. Then you are assessing maintenance, because you have to have a response in order to assess maintenance of that response. So the Dupi number is the maintenance of EASI-75.

Roger Song
Senior Analyst of US SMID Cap Biotech, Jefferies

Okay.

Jonathan Zalevsky
Head of R&D, Nektar Therapeutics

Yeah.

Roger Song
Senior Analyst of US SMID Cap Biotech, Jefferies

Yeah. Okay. Then the other thing is, for those patient into the maintenance is 50, I believe, and then they goes into the maintenance. How much selection bias do you think you will have for those 125?

Jonathan Zalevsky
Head of R&D, Nektar Therapeutics

Well, I mean, it is really the patient population that continued through the study, right? I mean, it is also indicative of the regimen, right? Because our whole kind of objective with all of these approaches, besides the differentiation, is really to define the regimen, right? One of the ways you could think about it is there is an induction regimen, which with REZPEG will be a twice-a-month dosage. We expect that for a period of six months, and that is how we designed the phase III. Then patients will move into maintenance on either a monthly or a quarterly regimen. But then you could imagine if we see durability off drug, as we think we will based on our phase I, then, for example, all patients could move to a once-a-quarter maintenance from years one onward.

And those would be some of the very unique ways and highly differentiating for this class, because right now, Dupixent is a drug that people take twice a month in perpetuity.

Roger Song
Senior Analyst of US SMID Cap Biotech, Jefferies

Got it. Then for the 52 weeks off treatment period, how would you handle those people drop off and then use rescue medicine? They will automatically become a non-responder, just they lose the-

Jonathan Zalevsky
Head of R&D, Nektar Therapeutics

Yeah. Firstly, like rescue medicine use in general has been really low in this trial. We just published in The Lancet the results of the induction. We actually will be submitting the results of the maintenance very soon as well. We have seen across the board just very low rescue med usage, which I think reflects the quality of the responses that patients are seeing when they are on REZPEG. Then in terms of how you handle it, again, this is an interesting study because even the Dupixent analogs, all of those people had access to extension studies later. So there is always sort of a chance for additional treatment. But in our study, there is not. People are just observed. So you kind of have a few different ways you can look at that.

You can look at the response that people have if they discontinue and when. Because again, there's not a lot of. Other than sort of the patient's altruism, they're off the study. For them to come back to the study site is really just them participating in the study. There's no kind of impetus for them otherwise. But we can look at things like the last observation carried forward, for example, to look at the response if a patient discontinues, and to correlate anything related to their discontinuation relative to efficacy at that time. We'll look at a number of different ways. Even if you review some of the literature, like the SOLO-CONTINUE trial from Dupixent that I'm mentioning, you can even see that they use multiple methodologies to handle patient dropouts and patient dispositions through that nine-month randomized withdrawal period.

Roger Song
Senior Analyst of US SMID Cap Biotech, Jefferies

Because those patients are not all EASI-75 at the end of maintenance, when you report at the end of 52 weeks of treatment, you will measure EASI-75 or 50? What would be considered as a responder?

Jonathan Zalevsky
Head of R&D, Nektar Therapeutics

Yeah. I think a good kind of comparison, similar to how we reported our maintenance data. We'll look at people that had a response, whether it's 50, 75, 90, IGA, or itch.

We'll look at the maintenance, or even EASI 100, and we'll look at the maintenance of that response. But then we'll also look at people that didn't have a response. Did they gain?

Roger Song
Senior Analyst of US SMID Cap Biotech, Jefferies

Yeah.

Jonathan Zalevsky
Head of R&D, Nektar Therapeutics

Right? Then looking, for example, we also reported the overall response rate, such as for IGA and EASI 100. So these are all very reasonable ways to look at the data, and they'll allow us to capture all of the elements of the mechanism.

Roger Song
Senior Analyst of US SMID Cap Biotech, Jefferies

Yeah.

Jonathan Zalevsky
Head of R&D, Nektar Therapeutics

And of course, this is off drug, right? So there's no more dosing, right? It's really just looking at the efficacy.

Roger Song
Senior Analyst of US SMID Cap Biotech, Jefferies

Yeah. Then probably more fair benchmark to the Dupi randomized withdrawal 50% is the patient at the end of maintenance, they are reaching EASI- 75, and then you look at those patients, how many, what percentage of those maintain the EASI- 75? That's probably-

Jonathan Zalevsky
Head of R&D, Nektar Therapeutics

Yeah. That is like the true definition of maintenance.

Roger Song
Senior Analyst of US SMID Cap Biotech, Jefferies

Yeah.

Jonathan Zalevsky
Head of R&D, Nektar Therapeutics

These are the people that had the response at time zero, and then how long did they keep that response over time?

Roger Song
Senior Analyst of US SMID Cap Biotech, Jefferies

That is right. Because, as you said, Dupi is kind of a, they have a sham, kind of a placebo, and then also they know they are going to get access to the extension. How much of the 50% will be inflated or deflated compared to your design?

Jonathan Zalevsky
Head of R&D, Nektar Therapeutics

Yeah. I mean, I think it is a great question, and we will report the results when they come. The other kind of, I guess, sort of maybe parallel is there was a small phase II study that rocatinlimab did. In their phase II, not in their phase III. But there, they treated people with an OX40 depleting antibody for 36 weeks. They had a 20-week off-drug observation. So much shorter period of time than, of course, we're doing, and even shorter than our phase I study.

They saw some durability, but there was quite a bit of erosion of efficacy in that study. But of course, that's a different mechanism of action. For us, that's an important comparator because the study design is similar, but it's the less relevant benchmark because that drug never made it, right? Whereas we see Dupixent as more relevant. It's by far, it's the drug that sells the most in atopic dermatitis. There's the most experience with it, and it's really the best understood mechanism.

Roger Song
Senior Analyst of US SMID Cap Biotech, Jefferies

Got it. Okay. We've spent a fair amount of time on this because this is more near-term catalyst or data because the design of the study, a little bit explanation is needed. Okay, let's quickly on the couple other things related to the atopic dermatitis. You also give us some updates on the phase III design, AD2. So you will add the redesign as the topical corticosteroid add-on. So, I know you're talking about the global regulator, and then they want to see some add-on results. How much the input from the FDA and the EMA for this design, and did they ask you to do that, and then how you will change your regulatory strategy in the U.S. and Europe?

Jonathan Zalevsky
Head of R&D, Nektar Therapeutics

I mean, I think that sort of capturing the global usage of systemic drugs and in different regions, kind of the desire and necessity to combine them with topical corticosteroid was definitely a driver. But for us, at the end of the day, this is really good news because this gives us the chance to develop really the most aggressive and differentiated label opportunity for REZPEG, because there's essentially all of the uses you could imagine would be a monotherapy in the biologic-naive patient population, which is the patient population in our ZENITH AD-1 trial. We're prospectively testing monotherapy in patients that have failed a biologic and/or a JAK inhibitor. It's very novel. I mean, we're going to prospectively test that in this patient population. That's the design of ZENITH AD-3. That gives a clear differentiating label for the second line plus.

Since topical corticosteroid combination is really commonly used in many, many regions, the design of ZENITH AD-2 is adding on the topical corticosteroid, so it is TCS plus placebo versus TCS plus REZPEG. That is in the mixed patient population of both naive and biologic-experienced and/or JAK-experienced patients. When you take a step back, that is basically every use category covered for REZPEG, and it gives us, again, very exciting label that could be very differentiated relative to the competition.

Roger Song
Senior Analyst of US SMID Cap Biotech, Jefferies

Because it is add-on, I do not believe you changed the sample size. How is the power change with the design change?

Jonathan Zalevsky
Head of R&D, Nektar Therapeutics

It is still very, very high, because there are 510 patients that we enroll in each of these three studies. If you look historically at TCS studies, there is a little bit of an increase in the placebo, but there is also an increase in the drug arm, and you still see very high separation. So within our power calculations and others, this is a very well-powered study. We are very confident about the design.

Roger Song
Senior Analyst of US SMID Cap Biotech, Jefferies

Any change recently for the topical steroid, corticosteroid, the performance at the placebo? No. Across different endpoint, I believe EASI-75 is slightly different from the IGA 0 and the one.

Jonathan Zalevsky
Head of R&D, Nektar Therapeutics

Well, I mean, yeah. All patients get drug, right, in those studies, so you do see a little bit of difference. But like I said, when we've looked across the results for Dupi, for lebri, for nemolizumab, which is all on topical combination anyway, you continue to see the separation. And certainly in our preclinical studies, we combined both a TCS and a TCI with REZPEG in a range of different dermatitis models, and the effect was at least additive. In many cases, it was actually highly synergistic. In fact, in many of those models, we could back way down on the dose of the steroid and still see the benefit of the combination.

Roger Song
Senior Analyst of US SMID Cap Biotech, Jefferies

Got it. Just last question on the AD, because as we said earlier, it's very active space, and then you do have for, along the Th2 kind of pathway, you continue to evolve in different ways to address the IL-13, IL-22, the IL-4, and then also you have a little bit novel oral and then some of the other mechanism still along the same kind of pathway. How do you think REZPEG can fit into the future AD space, and then what's your feedback you're getting from your physician advisors? And I do notice you have some benefit on the comorbidity, including asthma, so would that be a required meaningful differentiator for the REZPEG?

Jonathan Zalevsky
Head of R&D, Nektar Therapeutics

Yeah, I mean, we think yes to many of the things that you raised. I think I'll sort of start off with, as the R&D guy, one thing that was really exciting we demonstrated at EADV, a series of proteomic and transcriptomic analyses, both from skin samples collected of lesional atopic dermatitis lesions that were stripped with the tape, and also systemically by measuring serum, that as early as week two, after just a single dose of REZPEG, we were able to begin normalization of multiple systemic and local immunological pathways that are beyond Th2. So we saw Th1, Th2, Th17 pathways normalizing after just a single dose, as well as fibrotic signatures and even other disease-associated signatures around cardiac health and other kinds of immunological fitness.

What that starts to demonstrate for us is a clear separation that systemically, the immunological dysfunction that the patient has starts to reverse as early as a single dose, even faster than you see skin clearance, even faster than you see itch and other relief. So that means that REZPEG has this fundamental different way, right, that it can start to heal the patient's immune system. That, we think, now reflects the different sort of clinical properties that we're seeing with the REZPEG mechanism. One of those is the dual efficacy in the comorbidity of patients that have asthma and atopic derm at the same time.

Only Dupixent has been able to treat both until our data in phase II demonstrating that REZPEG also reaches that same benchmark and is able to really profoundly reduce the asthma patient-reported outcome issues that the patients are facing, with both severe uncontrolled as well as any asthma at all. We also mentioned in an earlier earnings call that patients with rhinosinusitis also demonstrated a benefit, and we will be presenting that data at a medical meeting in 2027, the early part of the year. That will capture both rhinosinusitis as well as comorbidity of allergy and rhinosinusitis. So that is a second element.

The third element is something we have been talking about before, that the durability that comes from fixing the immune dysfunction has a great effect on the symptoms, but we think is really modifying the underlying pathology of the disease, which then reflects to very low frequency dose interval and potentially longer and longer periods of durability after the cessation of treatment. All of these things we think position REZPEG in a very unique way to come in as a new MOA that can be very disruptive in this field.

Roger Song
Senior Analyst of US SMID Cap Biotech, Jefferies

Okay, great. We do not have much time left, but the focus was the atopic dermatitis. Alopecia areata, you are also moving to the phase III. One thing just want to highlight is you did not include any JAK inhibitor in the phase II, similar to the AD, but you separate the biologic JAK experience and the naive patient for the AD phase III, but you combine them in the alopecia areata. So how many patients you expect will enroll for those prior JAK, and then how you think you are going to impact the overall outcome? Would you stratify that?

Jonathan Zalevsky
Head of R&D, Nektar Therapeutics

Yeah. I mean, we have not guided to any of the specifics around that yet, but it will be what regulators want to see as a representative patient population. So representative means that, like, what would it be in real world? Well, in real world, some people take JAK inhibitors, but it is still a minority, right? The majority of patients are actually untreated with a JAK. So in our study, we would expect the majority of patients to be naive, by far.

We also, when we thought through putting that together, we do not see an issue or a risk of a patient that is a prior JAK inhibitor patient, because generally, these are people that have lost their hair, right? So we want to give them the opportunity to regrow it, since the JAK inhibitor that they had to discontinue, for most people, that will be for toxicity reasons, right? It was definitely holding back their progress, and we hope REZPEG can help them.

The other kind of key point for us is that the health authorities gave us the guidance that we can use a single phase III study to support that registrational approval. That study that kicks off for us next month will be an 850-patient trial in adolescents aged 12 and up, with a mixed population of naive and JAK-experienced patients, and we expect data in 2029 from that study.

Roger Song
Senior Analyst of US SMID Cap Biotech, Jefferies

Excellent. Thank you, J.Z.

Jonathan Zalevsky
Head of R&D, Nektar Therapeutics

Thanks, everyone.

Roger Song
Senior Analyst of US SMID Cap Biotech, Jefferies

Thank you, everyone.